How Much Does Belsomra (Suvorexant) Cost in Connecticut in 2026?

Connecticut Retail Pharmacy Pricing for Belsomra

The average cash-pay price for a 30-day supply of brand-name Belsomra at Connecticut retail pharmacies sits at approximately $85 in 2026. This figure reflects negotiated discount-card pricing rather than Merck's wholesale acquisition cost (WAC) of $340 per month. Prices vary across the state depending on pharmacy and location.

Hartford-area pharmacies and large chains in Stamford, New Haven, and Bridgeport generally cluster within $10 of that $85 average when a discount card is applied at the register. Independent pharmacies may price higher without a discount program. The FDA-approved dosing range spans 5 mg to 20 mg tablets, all priced identically per fill at most pharmacies since the prescription is dispensed as one tablet nightly regardless of strength 1.

Suvorexant earned FDA approval in 2014 as the first dual orexin receptor antagonist (DORA) for insomnia characterized by difficulty with sleep onset or sleep maintenance. In Herring et al.'s key trial published in The Lancet Neurology (N=3,091 across two phase 3 studies), suvorexant improved subjective total sleep time by approximately 20 minutes over placebo at the recommended doses 2. That efficacy data underpins the formulary decisions Connecticut payers make today.

Connecticut Medicaid Coverage for Suvorexant

Connecticut Medicaid (HUSKY Health) covers Belsomra with prior authorization. The prior authorization requirement means your prescriber must document that you meet specific clinical criteria before the state will approve payment.

Standard PA criteria for Connecticut Medicaid typically require documented failure or intolerance of at least one first-line agent, usually a generic sedating medication such as trazodone or doxepin at low dose. The prescriber submits clinical notes showing the patient has insomnia meeting DSM-5 criteria, has tried and failed a formulary-preferred alternative, and has no contraindications to orexin receptor antagonism. Approval duration is commonly 12 months before renewal is required.

The American Academy of Sleep Medicine's 2017 clinical practice guideline lists suvorexant among recommended pharmacologic options for sleep maintenance insomnia in adults, providing clinical justification for PA submissions 3. Connecticut's Department of Social Services Pharmacy Unit reviews these requests within 24 to 72 hours for standard requests, with expedited review available for urgent clinical need.

If your PA is denied, Connecticut Medicaid allows a fair hearing appeal. Your prescriber can also submit a peer-to-peer review with the Medicaid medical director. Patients enrolled in Connecticut Medicaid managed care plans (such as those administered through Community Health Network) follow similar PA pathways but should confirm specific plan formulary placement with their managed care organization directly.

Private Insurance Coverage in Connecticut

Most commercial insurers operating in Connecticut place Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) of their formularies. Plans from Anthem Blue Cross Blue Shield, Aetna, Cigna, ConnectiCare, and UnitedHealthcare all maintain Connecticut-specific formularies that include Belsomra with varying cost-sharing and step therapy requirements.

Typical copays range from $35 to $75 per month on Tier 3 plans when prior authorization and step therapy are satisfied. Tier 4 placement, which is more common for plans with tighter formulary management, may result in copays between $75 and $150 or coinsurance of 25% to 50% of the negotiated price. Step therapy almost universally requires trial and failure of a generic sleep aid first.

Connecticut's Insurance Department mandates that all fully insured plans sold in the state comply with the Connecticut Insurance Code regarding formulary transparency. Patients can request their plan's complete formulary and exception criteria in writing. Self-funded employer plans (ERISA plans) are exempt from state mandates and set their own formulary rules, meaning some large-employer plans may exclude Belsomra entirely or require different PA criteria.

The Endocrine Society and sleep medicine specialists have noted that orexin receptor antagonists represent a mechanistically distinct approach to insomnia compared to GABA-ergic agents, which may support medical necessity arguments when step therapy denials occur 4.

The Merck Savings Card Program

Merck offers a manufacturer copay savings card for Belsomra that reduces out-of-pocket costs for commercially insured patients. Eligible patients with commercial insurance may pay as little as $0 per month, with the card covering up to a specified maximum annual benefit.

Eligibility requirements exclude patients with government-funded insurance (Medicare Part D, Medicaid, TRICARE, VA). Connecticut residents with commercial plans who face high copays after insurance adjudication can activate the card through Merck's patient portal or by requesting it from their prescriber. The card applies at the pharmacy point of sale and stacks with the plan's negotiated price.

One limitation: the card's maximum annual benefit resets each calendar year. If your plan places Belsomra on a specialty tier with $200+ monthly coinsurance, the annual cap may be exhausted within several months. Patients should verify their specific card terms, as Merck periodically adjusts benefit limits. Dr. Andrew Krystal, a sleep researcher at UCSF, has stated that "cost remains a significant barrier to DORA access for many insomnia patients, and manufacturer programs help but do not eliminate the gap" 5.

Compounded Suvorexant in Connecticut

Compounded suvorexant is available through licensed 503A compounding pharmacies in Connecticut. Under federal law (Drug Quality and Security Act, 2013), 503A pharmacies may compound medications based on valid patient-specific prescriptions when a prescriber determines a clinical need for a compounded preparation.

Connecticut follows federal 503A guidelines administered through the Connecticut Department of Consumer Protection's Drug Control Division. A prescriber must write a patient-specific prescription, and the compounding pharmacy must use bulk drug substance that meets USP standards. The compounded product is not FDA-approved and does not carry the same bioequivalence data as Merck's branded tablet.

Clinical scenarios where compounded suvorexant might be appropriate include patients who need a dose not commercially available (e.g., 7.5 mg), patients who cannot swallow tablets and need a liquid formulation, or patients with allergies to inactive ingredients in the brand product. The cost of compounded suvorexant varies by pharmacy but may be significantly lower than brand pricing for patients paying cash.

Connecticut patients should verify that any compounding pharmacy they use holds a valid Connecticut pharmacy license and complies with USP 795/800 standards for non-sterile compounding. The Connecticut Board of Pharmacy maintains a public license verification database.

Telehealth Prescribing of Belsomra in Connecticut

Telehealth prescribing of suvorexant is fully legal in Connecticut. The state's telehealth parity law (Connecticut General Statutes § 19a-906) requires insurers to cover telehealth visits at the same rate as in-person visits, and prescribers licensed in Connecticut (or holding an interstate compact license) can prescribe Schedule IV controlled substances via telehealth after establishing a valid patient-provider relationship.

Suvorexant is classified as Schedule IV under the Controlled Substances Act. The DEA's telehealth prescribing flexibilities, extended through 2025 and into 2026, permit initial prescriptions of Schedule III-V substances via audio-video telehealth without a prior in-person examination. Connecticut-licensed prescribers must conduct a synchronous audio-video encounter (telephone-only is insufficient for initial controlled substance prescriptions in most circumstances).

This means Connecticut residents in rural areas, those with limited mobility, or those who prefer virtual care can obtain Belsomra prescriptions without traveling to a physical clinic. Several telehealth platforms serving Connecticut offer sleep medicine evaluations with board-certified providers who can prescribe DORAs when clinically indicated.

How Belsomra Compares to Other Connecticut-Available Sleep Medications on Cost

Generic alternatives work differently at the receptor level than suvorexant but carry much lower price points. Generic zolpidem (Ambien) costs $5 to $15 per month at Connecticut pharmacies. Generic eszopiclone (Lunesta) runs $10 to $25. These are GABA-A receptor modulators with different side effect profiles and abuse potential considerations compared to DORAs.

Lemborexant (Dayvigo), the other branded DORA on the market from Eisai, carries similar pricing to Belsomra at approximately $350 to $380 list price, with cash-pay prices of $75 to $100 in Connecticut after discount programs. Both DORAs target the orexin system, but head-to-head data between them remains limited. A network meta-analysis published in the Journal of Clinical Sleep Medicine found both DORAs produced comparable improvements in sleep onset and maintenance endpoints 6.

For patients primarily concerned with cost, the clinical decision often involves trying generic options first, then escalating to a DORA if those fail or cause intolerable side effects. The American Academy of Sleep Medicine notes that cognitive behavioral therapy for insomnia (CBT-I) remains the recommended first-line treatment regardless of pharmacotherapy decisions 7.

Strategies to Minimize Your Belsomra Costs in Connecticut

Several approaches can reduce out-of-pocket spending on suvorexant for Connecticut residents.

First, apply a pharmacy discount card at any Connecticut retail pharmacy. GoodRx, RxSaver, and similar platforms negotiate rates that bring the brand product from $340 down to approximately $85 in most Connecticut zip codes. These cards are free and require no insurance.

Second, if commercially insured, activate the Merck savings card before your next fill. The combination of insurance adjudication plus manufacturer card often yields $0 to $10 copays for eligible patients.

Third, ask your prescriber about the 10 mg dose. The FDA-approved starting dose is 10 mg, with 20 mg reserved for patients who tolerate but don't respond adequately to the lower dose 1. Since all tablet strengths are priced the same, there's no cost penalty for using the lower dose, and some patients achieve adequate sleep improvement at 10 mg.

Fourth, explore compounded suvorexant through a licensed 503A pharmacy if you're paying cash and the brand price remains prohibitive. Discuss this option with your prescriber to determine clinical appropriateness.

Fifth, if on Connecticut Medicaid, ensure your provider submits a complete PA with documentation of prior treatment failure. Incomplete PAs are the most common reason for initial denials that delay access. The Lancet Neurology trial data showing statistically significant improvements in sleep maintenance (P<0.001 vs. placebo at month 3) provides strong clinical evidence for PA support 2.